OncoMatch/Clinical Trials/NCT05210907

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Is NCT05210907 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SNUH-CD19-CAR-T for b-cell acute lymphoblastic leukemia.

Phase 1RecruitingSeoul National University HospitalNCT05210907Data as of May 2026

Treatment: SNUH-CD19-CAR-T — Chimeric antigen receptor T cells (CAR-T cells) have been developed to treat relapsed and refractory hematological malignancies with promising outcome in patients with very poor prognosis. The purpose of this clinical study is to produce the CD19\[cluster of differentiation antigen 19\] CAR-T (SNUH-CD19-CAR-T) at the investigational site and to evaluate safety and efficacy of SNUH-CD19-CAR-T in children and adolescent with relapsed/refractory B-cell acute lymphoblastic leukemia.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Lymphoblastic Leukemia

Biomarker criteria

Required: CD19 overexpression (positive by flow cytometry)

Documentation of CD19 tumor expression in bone marrow or peripheral blood by flow cytometry

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify